Mainland China funds increase stakes in Hong Kong biotech amid surge of licensing deals

A growing number of mainland Chinese institutional fund managers have built up stakes in Hong Kong-listed biotechnology stocks over the past month, drawn by attractive valuations amid a surge in cross-border licensing deals in the sector…